FEI Announces Quarterly Cash Dividend of $0.08 Per Share
HILLSBORO, Ore., Feb. 14, 2013 (GLOBE NEWSWIRE) -- FEI Company (Nasdaq:FEIC) announced that its board of directors has approved payment of a quarterly dividend of $0.08 per share of common stock. The dividend will be paid on April 23, 2013 to shareholders of record as of the close of business on April 10, 2013.
FEI Announces New Tecnai Arctica TEM for Structural Biology Research
HILLSBORO, Ore., Jan. 30, 2013 (GLOBE NEWSWIRE) -- FEI (Nasdaq:FEIC) today announced the availability of its Tecnai Arctica™ transmission electron microscope (TEM) for structural biology research. The Tecnai Arctica incorporates sophisticated automation, pioneered on FEI's flagship Titan Krios™ TEM, to elucidate the three-dimensional (3D) structure of biological macromolecules and molecular complexes. With the addition of the Tecnai Arctica, FEI now offers a portfolio of structural biology workflows to accommodate a broad range of facilities and budgets.
FEI Adopts Group Structure to Facilitate Further Growth
HILLSBORO, Ore., Jan. 14, 2013 (GLOBE NEWSWIRE) -- FEI Company (Nasdaq:FEIC) announced today that it is reorganizing the company into a group structure to enable it to efficiently execute its growth strategy. The company will be organized into two groups: an Industry Group, focused on customers making economic decisions to purchase and utilize FEI solutions that improve yield, reduce cost or speed time to market resulting in improved profitability; and a Science Group, focused on customers using FEI solutions to advance research and discovery.
FEI Unveils Broad Correlative Microscopy Solution Set for Cell Biologists
HILLSBORO, Ore., Nov. 26, 2012 (GLOBE NEWSWIRE) -- FEI (Nasdaq:FEIC) today announced a suite of solutions for correlative light and electron microscopy (CLEM). New methods in correlative microscopy from FEI bring data from different imaging techniques together automatically in minutes, giving cell biologists the precise information they need, when they need it. Scientists believe that correlating information from the cellular down to the molecular level will lead to breakthrough discoveries that improve their understanding and treatment of diseases, such as cancer, AIDS, and Parkinson's.